ViaNautis (formerly known as SomaServe), an innovative nanomedicine company based in Cambridge, UK, has recently secured $25 million in Series A funding through a round led by 4BIO Capital, BGF, and UCB Ventures. Additional investors include the Cystic Fibrosis Foundation, Eli Lilly and Company, and existing investors such as Origin Capital, Meltwind, and O2H. This influx of capital will enable ViaNautis to expedite the development of products utilizing their groundbreaking polyNaut® platform, expand their scientific and management teams, and establish state-of-the-art laboratory facilities.
Founded in 2018 as a spin-off from UCL, ViaNautis is under the astute leadership of CEO and serial entrepreneur, Dr.
Francesca Crawford. The company's flagship technology, PolyNaut®, boasts immense versatility as a nano-engineered polymer designed to facilitate targeted intracellular delivery. By utilizing polyNaut®, polymer nanoparticles can effectively transport various payloads, ranging from small molecules to genetic materials, effectively creating a "bionic nanoparticle." The unique polymer structure of polyNaut® allows it to encapsulate a wide array of genetic cargoes, surpassing current industry standards for viral and non-viral delivery methods. Furthermore, this cutting-edge technology significantly enhances the therapeutic efficacy of encapsulated molecules through direct delivery to the cell cytoplasm, made possible by the innovative GOTO® technology for intracellular shuttling.
The funding acquired by ViaNautis will provide the company with the necessary resources to push the boundaries of nanomedicine further. This investment will accelerate the development of novel products and techniques, bringing the promise of advanced medical treatments closer to reality. Additionally, the expansion of their scientific and management teams will nurture a vibrant research ecosystem, fostering collaboration and innovation in the field. By establishing state-of-the-art laboratory facilities, ViaNautis aims to further optimize their operations and solidify their position as a leader in nanomedicine technology.
|Business Name||ViaNautis Bio|
|Founder||Dr. Francesca Crawford|
|Investor||Cystic Fibrosis Foundation|
|Investor||Eli Lilly and Company|